ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

Completed · Phase 1

Conditions studied: Metastases, Cancer

In brief

This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.

Key facts

Study ID

NCT00034463

Run by

Eli Lilly and Company

Last updated by the study team

2006-07-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic or cytologic diagnosis of metastatic or locally advanced cancer
• Prior chemotherapy is allowed
• Adequate bone marrow, liver and kidney function

You may not qualify if…

• Prior treatment with ALIMTA
• Brain metastasis
• Pregnancy or breast feeding

Where it is running

• For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.